
Background Complement inhibitors are primarily used for symptomatic/refractory but stable myasthenic patients in the outpatient setting, however there is emerging data to suggest that complement inhibitors may be an effective rescue therapy in acute myasthenic exacerbation or crisis. Methods We present two cases of non-ventilator-dependent patients with refractory or recurrent myasthenic exacerbation in whom eculizumab was used as a rescue therapy, review the literature to date on inpatient use of complement inhibitor therapy for myasthenic crisis/exacerbation, and discuss the pathophysiology underlying rapid clinical response. Results Both patients had a rapid response to eculizumab with return of ability to speak and swallow within 48 h in one patient and reduction in MG-ADL score of >6 points within 2 weeks in one patient. Both achieved minimal symptom expression (defined as MG-ADL score of 0 or 1) within weeks and had sustained response to outpatient complement inhibitor therapy. Nineteen previously published papers (58 patients) were identified. Many patients had a clinically significant reduction in MG-ADL score or other objective evidence of clinical improvement within days, and had a sustained benefit with continued outpatient therapy. Conclusions Our findings add to a growing body of literature suggesting that complement inhibition may be a useful, fast-acting therapy for myasthenic exacerbation in the inpatient setting in some cases. This rapid response is likely due to functional complement blockade in patients with complement mediated neuromuscular junction damage as a primary cause of MG exacerbation/crisis.
Background Some patients with autoimmune encephalitis with anti-neuronal antibodies exhibit symptoms that resemble Parkinson-like disorders (an alternative term for atypical Parkinsonism) including progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy (MSA). Of the anti-neuronal antibodies, anti-neuronal cell-surface antibodies (NSAbs) are typically associated with a direct pathogenic role. In this study, we aimed to evaluate NSAbs in patients diagnosed with Parkinson-like disorders and characterize the clinical features of NSAb-positive patients. Methods We included 135 patients: 48 with PSP, 45 with CBS, and 42 with MSA. Clinical features were defined by the Movement Disorder Society PSP criteria, Armstrong criteria, and Movement Disorder Society MSA criteria, respectively. These patients were referred for antibody testing because of atypical clinical features or a suspected autoimmune etiology. We screened NSAbs in the cerebrospinal fluid of these patients using tissue-based assays on frozen rat brain sections and immunocytochemistry on rat hippocampal live neuronal cell cultures. For patients with positive findings, we examined NSAbs using cell-based assays. Results In two patients diagnosed with clinically probable MSA-cerebellar type, the presence of NSAbs was suggested by tissue-based assays and immunocytochemistry. Further analysis identified the target antigens of these NSAbs as seizure-related 6 homolog like 2 (Sez6l2) and metabotropic glutamate receptor 5 (mGluR5). Conclusions Our results suggest that some patients with clinical features of MSA may rarely have NSAbs associated with autoimmune encephalitis, including anti-Sez6l2 and anti-mGluR5 antibodies, potentially expanding the spectrum of autoimmune encephalitis that can mimic MSA.